[HTML][HTML] Promise and pitfalls of the Immunochip
Genomewide association studies (GWAS) have proven a powerful hypothesis-free method
to identify common disease-associated variants. Even quite large GWAS, however, have
only at best identified moderate proportions of the genetic variants contributing to disease
heritability. To provide cost-effective genotyping of common and rare variants to map the
remaining heritability and to fine-map established loci, the Immunochip Consortium has
developed a 200,000 SNP chip that has been produced in very large numbers for a fraction …
to identify common disease-associated variants. Even quite large GWAS, however, have
only at best identified moderate proportions of the genetic variants contributing to disease
heritability. To provide cost-effective genotyping of common and rare variants to map the
remaining heritability and to fine-map established loci, the Immunochip Consortium has
developed a 200,000 SNP chip that has been produced in very large numbers for a fraction …
Abstract
Genomewide association studies (GWAS) have proven a powerful hypothesis-free method to identify common disease-associated variants. Even quite large GWAS, however, have only at best identified moderate proportions of the genetic variants contributing to disease heritability. To provide cost-effective genotyping of common and rare variants to map the remaining heritability and to fine-map established loci, the Immunochip Consortium has developed a 200,000 SNP chip that has been produced in very large numbers for a fraction of the cost of GWAS chips. This chip provides a powerful tool for immunogenetics gene mapping.
Springer